E.COVID Biological Vaccine Gets India’s Emergency Approval For 12-18 Years Age Group

BENGALURU, Feb 21 (Reuters) – Indian vaccine maker Biological E. Ltd said on Monday its COVID-19 vaccine had received emergency use approval in the country for use in children aged 12 to 18. years.

The company’s vaccine, called Corbevax, is the third vaccine approved for use in children aged 12 and over in India, joining local player Bharat’s Zydus Cadila (CADI.NS) ZyCoV-D and Covaxin DNA vaccine. Biotech.

“This will further strengthen our fight against #COVID19,” India’s Health Minister Mansukh Mandaviya said in a tweet late Monday.

Join now for FREE unlimited access to Reuters.com


India has so far only started vaccinating children aged 15 and above. According to government figures, more than 76 million children between the ages of 15 and 17 have been vaccinated primarily with Covaxin.

The emergency use approval for restricted use in the 12-18 age group for Corbevax is based on interim results from an ongoing mid-to-late-stage clinical study, Biological E said. in an emailed statement.

At the end of December, Corbevax received emergency use authorization for adults, but it has not yet been included in the national vaccination programme. Read more

So far, nearly 1.76 billion vaccine doses have been used in India’s immunization program, of which about 84% were a domestic version of AstraZeneca’s (AZN.L) COVID-19 vaccine produced by Serum Institute of India.

India’s third wave of COVID-19 cases caused by the Omicron variant of the coronavirus has largely receded, with the country reporting 16,051 infections on Monday compared to more than 300,000 at the end of January.

Join now for FREE unlimited access to Reuters.com


Reporting by Anuron Kumar Mitra in Bengaluru; Additional reporting by Abhirup Roy; Editing by Shounak Dasgupta and Tomasz Janowski

Our standards: The Thomson Reuters Trust Principles.

Comments are closed.